Precision Oncology in Pancreatic Cancer and Future Treatment Directions DOI
Layal Al Mahmasani, Eileen M. O’Reilly

Surgical Oncology Clinics of North America, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker DOI Open Access

Nitzan Zohar,

Ryan Maguire,

Saed Khalilieh

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2848 - 2848

Published: March 21, 2025

Hypercapnia is a key feature of the respiratory microenvironment in many pathologic conditions. It occurs both as regional and systemic process, it associated with multiple metabolic changes such mitochondrial dysfunction, decreased ATP production, shift from glycolytic energy production to fatty acid metabolism. In cancer tumor microenvironment, hypercapnia has been linked at times enhanced cell migration, invasion, chemoresistance. Our previous work shown that hypercapnia-associated gene signatures can be used prognostic biomarkers. However, unlike hypoxia-inducible factor pathway, there are no validated targets quantify hypercapnia. this study, we investigated phenotypic transcriptomic occurring pancreatic ductal adenocarcinoma (PDAC) due chronic exposure hypercapnic atmospheres. We then identified SIAH3 hypercapnia-affected target explored its clinical relevance PDAC.

Language: Английский

Citations

0

Unlocking the Genetic Secrets of Pancreatic Cancer: KRAS Allelic Imbalances in Tumor Evolution DOI Open Access
Vasiliki Liaki,

Blanca Rosas-Pérez,

Carmen Guerra

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1226 - 1226

Published: April 4, 2025

Pancreatic Ductal Adenocarcinoma (PDAC) belongs to the types of cancer with highest lethality. It is also remarkably chemoresistant few available cytotoxic therapeutic options. PDAC characterized by limited mutational heterogeneity known driver genes, KRAS, CDKN2A, TP53, and SMAD4, observed in both early-stage advanced tumors. In this review, we summarize two proposed models genetic evolution pancreatic cancer. The gradual or stepwise accumulated mutations model has been widely studied. On contrary, less evidence exists on more recent simultaneous model, according which rapid tumor driven concurrent accumulation alterations. models, oncogenic KRAS are main initiating event. Here, analyze emerging topic allelic imbalances how it arises during evolution, as often detected metastatic PDAC. We affects biology, metastasis, response therapy. To extent, highlight necessity include studies frequencies design future strategies against

Language: Английский

Citations

0

Precision Oncology in Pancreatic Cancer and Future Treatment Directions DOI
Layal Al Mahmasani, Eileen M. O’Reilly

Surgical Oncology Clinics of North America, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0